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Synthetic heparan sulfate dodecasaccharides
reveal single sulfation site interconverts CXCL8
and CXCL12 chemokine biology†
Gordon C. Jayson,a Steen U. Hansen,b Gavin J. Miller,b Claire L. Cole,a
Graham Rushton,a Egle Avizienytea and John M. Gardiner*b
The multigram-scale synthesis of a sulfation-site programmed heparin-
like dodecasaccharide is described. Evaluation alongside dodecasac-
charides lacking this single glucosamine O6-sulfation, or having
per-O6-sulfation, shows that site-specific modification of the terminal
glucosamine dramatically interconverts regulation of in vitro and
in vivo biology mediated by the two important chemokines, CXCL12
(SDF1a) or CXCL8 (IL-8).
The glycosylaminoglycan (GAG) heparan sulfate (HS) is a linear
oligosaccharide polymer of alternating N-substituted glucosamine
(GlcN) and a hexuronic acid, which is either glucuronic acid
(GlcA) or the more conformationally-flexible iduronic acid (IdoA).
Chains of approximately 50 and up to B200 monosaccharides
are covalently linked to core proteins to form HS proteoglycans
(HSPGs) that are embedded in the cell membrane or extracellular
matrix, where they mediate interactions key to coordination of
signaling, proliferation and stem-cell diﬀerentiation.1 HS binds
over a hundred proteins2 and plays ubiquitous regulatory roles in
angiogenesis, inflammation and stem-cell diﬀerentiation and
thus HS-related oligosaccharides oﬀer numerous potential appli-
cations as therapeutics.3 Following the discovery of the specific
interaction between heparin and anti-thrombin III approximately
thirty years ago and the major medical importance of heparin,
there has been a continued search for H/HS-like structures with
defined biological structural specificity for other targets. The
success of Arixtra (Fondparinux) as a synthetic anti-coagulant
LMWH heparin (5-mer) has illustrated the clinical potential for
pure short synthetic heparin-related fragments.4 Much important
biological regulation is eﬀected by longer sequences and the
great heterogeneity of natural extracts makes synthetic routes
essential, however, particularly progression to in vivo biology of
any homogenous longer heparin-like oligosaccharides has been
precluded by lack of scalable syntheses. We recently exploited
large-scale iduronate synthesis5,6 to generate gram-scale quantities
of structurally-defined per-6-OH heparin-like dodecasaccharide 1.7
This iterative synthetic strategy was also applied to synthesis of the
new homogeneously per-6-O-sulfated heparin-like dodecamer 3.8
We report here application to synthesis of the first example of a site-
specifically mono-6-O-sulfated heparin-like dodecasaccharide, 2.
Provision of 2 on approximately 2 gram scale firmly establishes this
approach as a practicable general route to various long heparin-like
oligosaccharides on scales exceeding other GAG 12-mer syntheses
by two orders of magnitude and underpins the practicability of
delivering long synthetic GAGs for in vivo biology.
HS is organized into domains of high and low sulfation, with
high sulfation domains consisting predominantly of GlcN- and
O6, and IdoA O2 sulfation. These higher sulfation domains are
principal eﬀector parts of HS, binding ligand cytokines leading
to receptor activation.10,11 Identifying new, discrete synthetic
HS structures with defined biological eﬀects is central to under-
standing GAG microstructure-specificity and the potential for
discovery of new biomedical H/HS mimetics.12
GAGs are critically involved in chemokine biology, regulating
oligomerization and phenotypic eﬀects.13,14 HS-binding chemo-
kines CXCL8 (IL-8), CCL1915 and CXCL1216–18 (SDF-1a) are
involved in angiogenesis, metastasis and inflammation and are
thus high value biomedical targets. Specific effector HS ligands for
these chemokines remain undefined, and identification of specific
structures which differentially modulate biological activity of these
chemokines would provide new insight into GAG-chemokine
chemical biology and potential for new drug developments.
Considerable evidence indicates that the overall level of
glucosamine-6-O-sulfation is important for diﬀerential eﬀects
of H/HS oligosaccharides,19 and as a regulator of the biological
activity of several HS-dependent cytokines, such as CXCL813,20
and CXCL1220,21 as well as FGF222 and VEGF.14,21,23 Prior work has
indicated that homogenous sulfation levels and locations can aﬀect
the binding preferences of other GAGs to target proteins.24,25
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to investigate whether site-specific 6-O-sulfation variations can
determine biological eﬀect in longer native-like ligands.
The syntheses of a series of three sulfation-programmed oligo-
saccharides (Fig. 1, 1–3), and most particularly our capacity to
deliver much larger scale syntheses than previously available,
provides a tool-kit to interrogate the effects of both level and site-
specificity of defined sulfation in vitro and in vivo. We report here
that the presence or absence of a single site-specific sulfate inter-
converts CXCL8 or CXCL12 inhibitory effects between 1 and 2, both
in vitro and in vivo. These dramatic differential effects are not
evident for the per-6-O-sulfated dodecasaccharide analogue 3,
therefore indicating here that charge density is not a critical
mediator of cytokine-mediated effects, as previously suggested.22
Generation of novel HS 12-mer 2 with an additional O6-sulfate
at one specific terminus was achieved by capitalizing on the robust
scalability demonstrated for prior synthesis of homogenous
dodecasaccharides.7 Thus, 10-mer acceptor 4 was converted into
the protected 12-mer 6 by coupling with O6-modified disaccharide
donor 5,8 which programmes for subsequent GlcN 6-O-sulfation
at the non-reducing terminal unit only (Scheme 1), by tying the
ultimate O6-sulfation fate to that of iduronate O2. The GlcN-IdoA
disaccharide donor-based approach enabled this module switch to
provide batch synthesis of protected 12-mer, on 45 gram scale.
Saponification introduced free IdoA-2-OH groups and carboxylates
and released the key single terminal GlcN 6-OH, generating
partially protected 12-mer intermediate 6 on 3 g scale. O-Sulfation
of 6 (yielding 7) and subsequent debenzylation/azide reduction
using Pd(OH)2/C generated B2 g of the site-specifically GlcN-6-O-
sulfated penultimate dodecasaccharide 8. Final N-sulfation aﬀorded
the novel target dodecasaccharide 2 onB2 g scale, demonstrating
the generic scalability of this iterative synthetic approach.7,8
The homogeneity of all materials was unambiguously con-
firmed by LCMS, MS and 800 MHz HSQC NMR analyses. Most
particularly, ESI mass spectral data were fully consistent with a
mono-O6-sulfated species, whilst the HSQC data provided
confirmation of single site of sulfation significantly diﬀeren-
tiated from the main-chain C6 methylene units (Fig. 2).
This scalable access to the mono-6-O-sulfated dodecasac-
charide 2 alongside fully 6-O-desulfated 12-mer, 17 and the fully
6-O-sulfated 12-mer 3,8 provided a toolkit to evaluate the
biological eﬀects of modifying a single sulfation site at the
non-reducing terminal glucosamine in long synthetic heparin-
like species, as well as control evaluation of full O6-sulfation
both in a otherwise identical synthetic 12-mer (3) and a digest
HS 12-mer. It must be emphasized that whilst all synthetic
sequences shared the same terminal 4-O-sulfate, digest HS –
the regular standard in biological assays – also lacks a 4-OH
as digests contain a terminal unsaturation, and thus there is
no rationale to consider the inclusion or absence of a 4-OH
relevant, as this is invariably also a synthetic construct from
other synthetic routes. Further, it is noted that the only variable
between the synthetic species were 6-O-sulfation changes and
any hypothetical relative effects from a 4-O-sulfate should
therefore be discounted.‡ This is further supported by our
migration and pERK signaling assays comparing synthetic
4-OS-terminated per-6-OS sequence 3 with commercial digest-
derived dp12 (ESI,† Fig. S25). Therefore, the 4-OS is a constant
and not an effector and this establishes that 4-OS terminated
heparin-like oligosaccharides are bioactive in vitro and in vivo
and thus also may adapt future approaches to synthesis of such
oligosaccharides.
Multiple experimental models of cytokine-elicited endothelial
cell biological responses provided clear, consistent evidence of an
orthogonal impact on the biological eﬀects of CXCL8 and CXCL12
by synthetic dodecasaccharides bearing either no sulfates on
GlcN-O6 (1) or a single, non-reducing end GlcN-O6 sulfate (2).
The fully 6-O-sulfated dodecasaccharide 3 did not show this
inhibition switching, and its behaviour was very similar to that
Fig. 1 Site-specifically 6-O-sulfated dodecasaccharides: completely non-6-
O-sulfated 1,5 site-selectively mono-6-O-sulfated 2 and fully 6-O-sulfated 3.6
[Blue shading: 6-OH microdomain; red-shading: 6-OS microdomain].
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of de-polymerised digest dp12 derived from commercial heparin
(ESI,† Fig. S25). This strongly reinforces evidence that the single site
sulfation is the unique diﬀerential regulating this switch in
chemokine eﬀects and that that is indeed structure-specific.§
Specifically, cytokine-induced endothelial cell monolayer wound
healing models show strikingly diﬀerent eﬀects of dodecasac-
charides 1–3 on CXCL8 and CXCL12-elicited endothelial migration
(Fig. 3a and b, dotted boxes). Dodecasaccharide 1 was the most
potent inhibitor of CXCL8-induced migration (Fig. 3a), but the
weakest inhibitor of CXCL12-induced migration, whereas site-
specifically sulfated 2 was the most potent inhibitor of CXCL12,
whilst 1 showed very limited effect (Fig. 3b). Thus, addition of
a 6-O-sulfate converts CXCL8-induced endothelial cell migration-
inhibiting 12-mer 1 into a CXCL12-induced inhibitor 2. The
reversal of effects is highlighted by blue-dashed boxes in Fig. 3.
The eﬀects on downstream signaling of the three dodeca-
saccharides on CXCL12-induced ERK1/2 phosphorylation and
on CXCL8-induced STAT3 phosphorylation showed the same
striking orthogonality of eﬀects for 1 and 2. The most potent
inhibition of CXCL12 signaling (75% at 10 mg ml1) was
eﬀected with site-specifically sulfated 2 while the most eﬀective
inhibitor of CXCL8 was 1, reducing STAT3 phosphorylation
480% at 1 and 10 mg ml1 (ESI,† Fig. S23).
To further validate the in vitro diﬀerential eﬀects of the
single sulfation-site programming and to show that this is
specific for CXCL8–CXCL12, the effects of 1 and 2 on leukocyte
transmigration through an endothelial monolayer were evaluated.
Parallel experiments were undertaken using the homeostatic
chemokine CCL19. Dramatic, near-orthogonal on-off relationships
with respect to CXCL8 and CXCL12 were observed with 1 and 2
(Fig. 3c and d: red-dashed boxes illustrate the reversal of effects).
In contrast, the impact of oligosaccharides on CCL19-mediated
migration (Fig. 3e) showed similar and incomplete levels of
inhibition with both 1 and 2. These data demonstrate that
regulation of the biology of specific chemokines can bemediated
solely by the presence or absence of a single 6-O-sulfate moiety
in a synthetic dodecasaccharide backbone, and regulate only
specific chemokines.
Prior seminal work on in vivo biology of long H/HS has
employed digest-derived heterogeneous HS26 and more recent
studies also have evaluated non-GAG synthetic mimetics.27,28
Synthesis reported here of grams of structurally-defined oligo-
saccharides 1 and 2 enabled us to conduct the first in vivo
studies with such oligosaccharides, in several biological models.
Most importantly, was the objective of identifying whether the
remarkable in vitro switch eﬀects (vide supra) were observed
in vivo. CXCL8 or CXCL12 and oligosaccharide-impregnated
sponges were implanted subcutaneously in mice to determine
the eﬀects of the oligosaccharides on chemokine-induced biology
(Fig. 4). CXCL8-mediated vascular density and neutrophil infiltra-
tion (Fig. 4a and b) were significantly inhibited by 1, whereas
site-specifically sulfated analogue 2 was ineﬀective. The converse
situation was seen in inhibiting CXCL12-induced repopulation
of sponges with host vasculature (Fig. 4c), infiltration of neutro-
phils (Fig. 4d) and macrophages (Fig. 4e, ESI,† Fig. 25a–e). These
in vivo data show dramatically changed selectivity of the in vivo
biological effects between the dodecasaccharides 1 and 2, corre-
lating with all the cell biology and signaling data. The only
difference between 1 and 2 is the addition of a single site-specific
GlcN6S in 2. This is the first evidence for such defined degree of
site-sulfation structural specificity modulating in vivo effects.
In summary, we demonstrate that an eﬃcient iterative
chemical strategy now extends to multigram scale synthesis
Fig. 2 Site-specifically 6-O-sulfated dodecasaccharides: structural charac-
terization. (a) 800 MHz HSQC NMR data confirming terminal ring 6-O-
sulfation of dodecasaccharide 2 (HSQC overlay data for 2 and 1; Fig. S22 in
ESI,†). (b) (i) MALDI-TOF mass spectral base peak [M + Na]+ for the fully-
protected species (ii) ESI mass spectral data for dodecasaccharide 8 (iii) ESI
mass spectral data for site-specifically sulfated dodecasaccharide 2.
Fig. 3 Diﬀerential eﬀects of 12-mers 1–3 on CXCL8 and CXCL12-
mediated functions, in vitro. (a and b) HUVEC migration in response to
(a) CXCL8 and (b) CXCL12 12-mers in wound-healing assay. [1, 2 and 3 at
1 mg ml1 (white), 10 mg ml1 (grey) or 50 mg ml1 (black). Area repopulated
in 24 h as percentage of the effect of cytokine without oligosaccharides
(=100%)]. *, po 0.001; †, po 0.01; ‡, po 0.05. (c–e) Inhibition of CXCL12,
CXCL8 and CCL19-mediated leukocyte transmigration through an
endothelial monolayer by 1 and 2. Two experiments data as mean  SD.
* po 0.01; ‡, po 0.05. (c)–(e) Non-significant differential impacts of 1 and
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of a site-specifically sulfated dodecasaccharide establishing this
as a general gram-plus scale access to diﬀerentiated, structure-
programmable synthetic dodecasaccharides. This has thereby
also enabled the first in vivo studies with such pure longer
H/HS oligosaccharides. Addition of a single 6-O-sulfate moiety
to the non-reducing end of an otherwise homogeneously sulfated
dodecasaccharide eﬀects a switch between inhibition of CXCL12
and CXCL8, showing that sulfate location specificity can be a key
determinant of biological eﬀects. Such reversal of eﬀects is not
seen with a key control chemokine CCL19, and nor is it seen with
angiogenic growth factors (VEGF, FGF2). These findings indicate
that other significant site-specific sulfation-determined eﬀects
await discovery and biomedical exploitation.
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Communication ChemComm
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
2 
Ju
ly
 2
01
5.
 D
ow
nl
oa
de
d 
on
 3
0/
11
/2
01
5 
09
:0
4:
25
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
